GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

Stopping prescription weight loss drugs often leads to significant weight regain, according to a large-scale analysis of 11 ...

A new study in mice has found that muscle loss associated with weight loss from GLP-1 medications like Ozempic may not be as ...

ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...

Key Takeaways More than 1 in 10 Americans has tried a GLP-1 drug50- to 64-year-olds report the most useSide effects like ...

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

The glucagon-like peptide 1 (GLP-1) market is projected to grow at a CAGR of 6.48%, during the forecast period of 2022-2027.

Projections for the near future indicate that the glucagon-like peptide GLP-1 agonists weight loss drugs market size will continue to surge, reaching $28.91 billion in 2029 at a CAGR of 16.6%.

Results confirm previous findings that nonarteritic anterior ischemic optic neuropathy (NAION) was more likely in those who ...

The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $20.88 billion in 2024 to $22.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The ...